Skip to content

Perspective Therapeutics CATX Purchases of fixed maturity securities

Purchases of fixed maturity securities at other companies

uniQure logo
uniQureQURE
$441.25M+450%
Roivant Sciences logo
Roivant SciencesROIV
$0-100%

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireHeldToMaturitySecurities.

The official record: Perspective Therapeutics’s 10-K, filed March 16, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's purchases of fixed maturity securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's purchases of fixed maturity securities?
Perspective Therapeutics (CATX) reported purchases of fixed maturity securities of $0 in Q4 2025.
What does purchases of fixed maturity securities mean?
Cash spent purchasing fixed-income securities (bonds, notes, debentures) for the investment portfolio.